FORA Capital LLC Invests $1.79 Million in TransMedics Group, Inc. (NASDAQ:TMDX)

FORA Capital LLC acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 28,675 shares of the company's stock, valued at approximately $1,788,000. FORA Capital LLC owned about 0.09% of TransMedics Group at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Frontier Capital Management Co. LLC purchased a new stake in shares of TransMedics Group in the fourth quarter worth approximately $9,415,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in shares of TransMedics Group by 40.1% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 7,290 shares of the company's stock worth $455,000 after buying an additional 2,086 shares during the period. Divisadero Street Capital Management LP raised its holdings in shares of TransMedics Group by 312.8% in the fourth quarter. Divisadero Street Capital Management LP now owns 158,480 shares of the company's stock worth $9,881,000 after buying an additional 120,090 shares during the period. Cetera Investment Advisers raised its holdings in shares of TransMedics Group by 8.3% in the fourth quarter. Cetera Investment Advisers now owns 8,260 shares of the company's stock worth $515,000 after buying an additional 634 shares during the period. Finally, Centiva Capital LP raised its holdings in shares of TransMedics Group by 156.0% in the fourth quarter. Centiva Capital LP now owns 31,087 shares of the company's stock worth $1,938,000 after buying an additional 18,943 shares during the period. 99.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Piper Sandler restated an "overweight" rating and set a $125.00 price objective (up from $105.00) on shares of TransMedics Group in a report on Friday. Canaccord Genuity Group restated a "buy" rating and set a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Oppenheimer raised their price objective on TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a report on Friday. Finally, Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.70.

TransMedics Group Trading Up 19.6%

TransMedics Group stock traded up $18.30 during trading on Friday, hitting $111.50. The company had a trading volume of 4,541,391 shares, compared to its average volume of 1,348,071. The company's 50 day simple moving average is $78.53 and its 200-day simple moving average is $75.10. The stock has a market cap of $3.77 billion, a price-to-earnings ratio of 118.62 and a beta of 1.91. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company's quarterly revenue was up 48.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.35 earnings per share. As a group, analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.